Labcorp’s first quarter saw steady execution in a complex environment, with results that prompted a positive market response. Management pointed to volume recovery in its Diagnostics Laboratories segment, following early quarter weather disruptions, and highlighted momentum from recent acquisitions such as Invitae. CEO Adam Schechter credited “strong managed care access and our payer contracts” for supporting growth, while noting that operational efficiencies helped offset inflation in personnel costs. The biopharma laboratory services segment also contributed, with improved margins and a robust book-to-bill ratio.

Is now the time to buy LH? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Labcorp’s Q1 Earnings Call

• Michael Cherny (Leerink Partners) asked about macro volatility affecting Biopharma Laboratory Services; CEO Adam Schechter explained the guidance range accommodates potential regulatory and trial timing uncertainties but reported no major study delays so far.
• Ann Hynes (Mizuho) questioned how tariffs are reflected in guidance; Schechter described diversified sourcing strategies and said most vendor spend is under contract, minimizing direct exposure to new tariffs.
• Erin Wright (Morgan Stanley) inquired about the organic growth split in Diagnostics; CFO Julia Wang clarified that after adjusting for weather impacts, underlying growth trends remain in line with historical expectations, with volume and price mix both contributing.
• Lisa Gill (JP Morgan) probed about the impact of potential regulatory changes in animal testing for early development; Schechter stated the affected revenue is limited to 10–15% of Biopharma segment, with immaterial impact at the enterprise level.
• Jack Meehan (Nephron Research) asked about Invitae integration and its path to accretiveness; Schechter detailed steps taken to merge operational best practices and confirmed positive earnings contribution is expected in the second half of the year.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will watch (1) the pace of integration and earnings contribution from recent acquisitions such as Invitae and BioReference Health assets, (2) the success of new test launches in high-growth therapeutic areas and their impact on volume and pricing mix, and (3) the company’s ability to sustain margin improvement while absorbing tariff and regulatory changes. Additionally, progress on securing additional lab management agreements and further M&A activity will be key markers of execution.

Labcorp currently trades at $261.88, up from $230.01 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.